Adding the drug triapine to radiation for glioblastoma or astrocytoma that has come back
Original title: Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people, done to find a safe dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests giving a drug called triapine along with radiation for a brain tumor that has come back.
Who this trial is for. This trial is for people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary or astrocytoma that has come back after a period of improvement. It tests triapine given together with radiation therapy. The study looks at safety, side effects, and the best dose.
Where it stands. This trial has not reported results. It is measuring how safe the combination is, what side effects people have, and what dose works best. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Triapine may slow tumor cell growth by blocking some enzymes that cells need to grow. Radiation uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. This study is checking whether the two together are safe and can be tolerated. If your tumor has come back, you could ask your care team whether a study like this makes sense for you.
What it doesn't mean: This does not mean triapine with radiation works. A trial is a test, not a proven treatment. Joining a study is not a guarantee that it will help you, and side effects are possible. This is not a cure, and it is not a promise of one. Whether anyone can join is decided by the trial team.
Source: ClinicalTrials.gov, July 31, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.